JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (11): 64-68.doi: 10.6040/j.issn.1671-7554.0.2015.338

• Clinical Medicine • Previous Articles     Next Articles

Effect of lansoprazole and exenatide on gastrin and oxyntomodulin in patients with type 2 diabetes

LI Hanbing, GAO Yanyan, LI Li, CAO Caixia, XIAN Yuxin, WANG Jing, NIU Jiapeng   

  1. Department of Endocrinology, East Hospital, the Affiliated Hospital of Qingdao University, Qingdao 266100, Shandong, China
  • Received:2015-04-01 Online:2015-11-10 Published:2015-11-10

PDF (PC)

160

Abstract: Objective To observe glucose and lipids levels, body composition and insulin sensitivity before and after the treatment of exenatide and lansoprazole in type 2 diabetes mellitus (T2DM) patients, and to explore the effects of lansoprazole on the serum gastrin and oxyntomodulin (OXM). Methods Fifty-four obese patients with T2DM were randomly divided into combined treatment group (n=27) and exenatide group (n=27). Therapeutic plan of combined treatment group: 10 μg exenatide (subcutaneous injection one hour before breakfast and dinner) plus 15 mg lansoprazole were applied based on the original scheme; therapeutic plan of exenatide group: 10 μg exenatide (subcutaneous injection one hour before breakfast and dinner) was applied based on the original scheme. After 8 weeks of treatment, the changes in weight, body composition, blood pressure, fasting blood glucose (FBG), serum lipids, hepatic and renal functions, fasting insulin, glycosylated hemoglobin (HbA1c), insulin resistance index (HOMA-IR), serum gastrin and OXM were measured. Results Body weight, body composition, low densith lipoprotein (LDL), FBG, HbA1c, HOMA-IR and systolic pressure decreased significantly after treatment in both two groups (P<0.05). Comapred withexenatide group, gastrointestinal discomfort was alleviated, serum gastrin level increased [(160.76±8.93) vs (95.30±6.01) ng/L, P<0.05], FBG [(8.06±2.33) vs (8.51±2.71)mmol/L, P<0.05] and HbA1c[(7.79±0.78) vs (7.87±0.81)%, P<0.05] levels decresed in combined treatment group. The changes of ALT, AST, uric acid (UA), serum creatinine (Scr), blood urine nitrogen (BUN), high density lipoprotein (HDL) and OXM in two groups had no statistical differences (P>0.05). Correlation regression analysis showed that the decrease of HbA1c was associated with the increase of gastrin after treatment of exenatide and lansoprazole(r=-0.302, P<0.05). Conclusion Lansoprazole can alleviate gastrointestinal discomfort caused by exenatide in the early stage and reduce the blood glucose levels in obese T2DM patients, which may be related to the increase of gastrin. However, lansoprazole may have not any effects in the changes of oxyntomodulin.

Key words: Type 2 diabetes mellitus, Exenatide, Lansoprazole, Gastrin

CLC Number: 

  • R589
[1] Patel V, Joharapurkar A, Dhanesha N, et al. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice[J]. Pharmacol Rep, 2013, 65(4):927-936.
[2] U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years therapy of type Ⅱ diabetes a progressive disease. [J]. Diabetes, 1995, 44(11):1249-1258.
[3] Motoyuki T, Yoshio F, Toyoyoshi U, et al. Combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation[J]. Diabetes Investig, 2010, 1(5):172-183.
[4] Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice[J]. Diabetes, 2008, 57(12):3281-3288.
[5] Spencer CM, Faulds D, Lansoprazloe. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders[J]. Drugs, 1994, 48(3):404-430.
[6] Takebayashi K, Sakurai S, Suzuki T, et al. Effect of combination therapy with alogliptin and lansoprazole on glycemic cntrol in patients with type 2 diabetes[J]. Endocr J, 2014, 61(10):1031-1039.
[7] Singh PK, Hota D, Dutta P, et al. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial [J]. J Clin Endocrinol Metab, 2012, 97(11):E2105-E2108.
[8] Bödvarsdóttir TB, Hove KD, Gotfredsen CF, et al. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes [J]. Diabetologia, 2010, 53(10):2220-2223.
[9] Mefford IN, Wade EU. Proton pump inhibitors as a treatment method for type II diabetes[J]. Medical Hypotheses, 2009, 73(1):29-32.
[10] Yaron S, Judith M, Miri SR, et al. Gastrin: a distinct fate of neurogenin3 positive progenitor cells in the embryonic pancreas [J]. PLoS One, 2013, 8(8): e70397. doi:10.1371/journal.pone.0070397.
[11] Wang M, Racine JJ, Song X, et al. Mixed chimerism and growth factors augment beta cell regeneration and reverse late-stage type 1 diabetes [J]. Sci Transl Med, 2012, 4(133):133-159.
[12] Rooman I, Bouwens L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycemia in C57B16/J mice treated with alloxan[J]. Diabetologia, 2004, 47(2):259-265.
[13] 郭娅棣,高燕燕,李莉,等.兰索拉唑对2型糖尿病患者血糖及胃泌素的影响[J].山东大学学报:医学版, 2013, 51(7): 62-66. GUO Yadi, GAO Yanyan, LI li, et al. Effects of lansoprazole therapy on the plasma glucose and gastrin in the patients with type 2 diabetes mellitus[J]. Journal of Shandong University: Health Sciences, 2013, 51(7):62-66.
[14] Alessandro P. Action and therapeutic potential of oxyntomodulin[J]. Mol Metab, 2014, 3(3):241-251.
[15] Kosinski JR, Hubert J, Carrington PE, et al. The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin[J]. Obesity, 2012, 20(8):1566-1571.
[16] Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes[J]. Vasc Health Risk Manag, 2009, 5(1):199-211.
[17] Macconell L, Brown C, Gurney K, et al. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes:integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials[J]. Diabetes Metab Syndr Obes, 2012, 5:29-41.
[1] LI Shuai, WANG Yalin, SUN Zhongwen, ZHU Meijia. Expression changes and mechanism of Nod-like receptor protein 3 inflammasome in the cerebral microvascular endothelial cells in type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 6-11.
[2] PENG Li, QIANG Ye, ZHAO Huichen, CHEN Shihong, YAO Weidong, LIU Yuantao. Clinical studies on type 2 diabetic patients treated with sitagliptin [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 60-63.
[3] LIN Dong, GUAN Qingbo. Association of serum testosterone level and non-alcoholic fatty liver disease in male patients with T2DM [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 33-37.
[4] Muhadasi TUERXUNYIMING, Patamu MOHEMAITI, Tuolanguli MAIMAITIKUERBAN. Association of CDKAL1 rs10946398 C/A polymorphism with type 2 diabetes [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(2): 75-85.
[5] YU Ning, GAO Yanyan, XIAN Yuxin, NIU Jiapeng, LI Li, WANG Jing, CAO Caixia. Effect of exenatide on serum chemerin level and liver fat contents in type 2 diabetes mellitus combined with non-alcoholic fatty liver disease patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(11): 51-55.
[6] LIU Yanxun, LIU Jia, ZHANG Tao, WANG Lu, XUE Fuzhong, WANG Ping. Type 2 diabetes mellitus associated with thyroid nodules: a longitudinal health check-up cohort study [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(8): 83-86.
[7] PEI Leilei, SUN Zhonghua, LI Zhe, ZHAO Wenping. Effects of sitagliptin combined with high-dose insulin on type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 39-42.
[8] HU Fangzhi, ZHANG Zhengjun, GENG Houfa, LIANG Qiuhua, SUN Lin. Relationship between microalbuminuria and brain damage in patients with type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 43-47.
[9] LI Fang. Association between receptor of advanced glycation end products gene polymorphisms, soluble receptor of advanced glycation end products and susceptibility of type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(12): 57-61.
[10] DING Juan, ZHENG Guixi, DU Lutao, YIN Zuohua, ZHANG Jian, WANG Chuanxin. Evaluation of combined detection of sHLA-G, PGR and GPR in the diagnosis of gastric cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(11): 59-63.
[11] ZHANG Nan1, YUAN Zhongshang2, ZHANG Xu1, ZHANG Yikun1, YU Chunxiao1, GAO Ling3, ZHAO Jiajun1, GUAN Qingbo1, GUAN Liying4. Association between serum testosterone and lipid profile in men with type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(4): 58-61.
[12] GUO Ya-di, GAO Yan-yan, LI Li, SUN Rui-xia, WANG Jing, XIAN Yu-xin. Effects of lansoprazole therapy on the plasma glucose and gastrin in the patients with type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(7): 62-66.
[13] LIU Wen-ting1, HU Yi-jun1, CHEN Li2, JIANG Guang-shui1. Quantitative analysis of Clostridium leptum subgroup in patients with chronic periodontitis and type 2 diabetes mellitus [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(4): 100-104.
[14] ZHANG Min1, GENG Hou-fa2, SUN Lin2. Quantitative evaluation of brain metabolic changes in patients with acute cerebral infarction and type 2 diabetes mellitus using proton magnetic resonance spectroscopy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(11): 74-77.
[15] ZHANG Hui-feng1， ZHOU Jia-long1， SHENG Wen-hua2，3. Relationship between blood glucose level and PSGL-1 expression in acute cerebral infarction patients with type 2 diabetes mellitus and its significance [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(10): 66-69.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd